EA8192, led by Jean Hoffman-Censits and Petros Grivas, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: bit.ly/ea8192-trial #blcsm

To all oncologists,

It's vital to recognize: “Patients with resectable disease have better outcomes, and you can’t account for that without randomizing.” #hncsm

This truth is universal across ALL disease sites! #blcsm #esocsm #hpbcsm #kcsm #lcsm

#radonc #surgonc #ESTRO24

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer. Jonathan Rosenberg MD Memorial Sloan Kettering Cancer Center #blcsm #oncology onclive.com/view/adcs-and-…

Preoperative circulating tumor DNA (ctDNA) status predicts oncologic outcomes following radical cystectomy for bladder cancer. brnw.ch/21wJBiS #AUA24 #blcsm

TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer. Tonivilaseca #oncology #AUA2024 #MedTwitter #blcsm onclive.com/view/tar-210-d…

Nogapendekin alfa inbakicept-pmln plus BCG provides a feasible, effective treatment alternative to patients with BCG-unresponsive NMIBC who would otherwise undergo radical cystectomy. UCLA Urology #blcsm #oncology onclive.com/view/n-803-bcg…

May is #BladderCancerMonth24 and watch out for our weekly podcast on our website this Friday with our special guest Rob Jones, who will talk on:

⭐ #Bladdercancer management in the UK
⭐Improving 1L treatment in BC
⭐Survivorship challenges

Here's a 30 sec preview🎙️

#blcsm

Clinicians should counsel and manage patients who have even a mild history of venous thromboembolism before they undergo radical surgery for urothelial carcinoma because these patients have increased risk for postoperative complications. brnw.ch/21wJB8o #AUA24 #blcsm

Voiding dysfunction affects approximately 1 in 6 older patients treated for nonmuscle-invasive bladder cancer (NMIBC) by 5 years after diagnosis, investigators reported at #AUA24 . brnw.ch/21wJCPi #blcsm

Voiding dysfunction requiring therapy affects a significant proportion of older patients treated for NMIBC. brnw.ch/21wJB3A #AUA24 #blcsm

This May is #BladderCancerMonth24 and watch out for our weekly podcast on our website this Friday with our special guest Jonathan Rosenberg MD who gives updates in ADCs including:

⭐The future of EV + pembro
⭐SG + other ADCs
⭐Managing toxicities

Here's a 30 sec preview 🎙️

#blcsm

Dr. Patrick Soon-Shiong discusses the recent FDA approval of N-803 for BCG-unresponsive NMIBC. Dr. Pat Soon-Shiong #blcsm #urology
urologytimes.com/view/dr-soon-s…

The gene therapy nadofaragene firadenovec led to durable antitumor activity in a subset of patients with BCG-unresponsive NMIBC. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…

Bladder Cancer Awareness Month! 🧡 “nobody walks alone”
Join in to raise awareness and research dollars across the country with local community & independent walks 🧡 Thank you #AUA24 IBCG Bladder Cancer Advocacy Network #blcsm #blcam

WATCH: Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in #NMIBC and unmet needs in this patient population. #BLCSM #AUA24 #AUA2024 | UCSF Health

targetedonc.com/view/about-the…

Check out this fascinating story from Bhardwaj Lab on NK cells in bladder cancer. #BladderCancerAwarenessMonth #blcsm #bladdercancer
Natural Killer Cell Dysfunction In Human Bladder Cancer Is Caused By Tissue-Specific Suppression of SLAMF6 Signaling
biorxiv.org/content/10.110…

Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines [May 20, 2022] Yap et al. JAMA Network Open jamanetwork.com/journals/jaman… #PrecisionMedicine #geneticcounselors #blcsm #lcsm Tempus

TAR-200 Leads to Durable Responses in Bacillus Calmette–Guérin-Unresponsive NMIBC
Amer. Urol. Assn. #AUA24 #AUA2024 #NMIBC #blcsm #MedTwitter #oncology
onclive.com/view/tar-200-l…

“Radical cystectomy is a life-changing operation with considerable morbidity and quality of life considerations. Moreover, there is a 90-day mortality risk of up to 8%,” said Joseph Jacob, MD, MCR. #blcsm #AUA24 | Amer. Urol. Assn. Joe Jacob MD, MCR

cancernetwork.com/view/lasting-r…